Published in Protein Sci on February 01, 2011
Vitronectin inhibits neutrophil apoptosis through activation of integrin-associated signaling pathways. Am J Respir Cell Mol Biol (2012) 0.88
Crystal structure of plasminogen activator inhibitor-1 in an active conformation with normal thermodynamic stability. J Biol Chem (2011) 0.84
Metals affect the structure and activity of human plasminogen activator inhibitor-1. II. Binding affinity and conformational changes. Protein Sci (2011) 0.83
Vitronectin inhibits efferocytosis through interactions with apoptotic cells as well as with macrophages. J Immunol (2013) 0.81
Application of long-acting VLHL PAI-1 during sutureless partial nephrectomy in mice reduces bleeding. Biomed Res Int (2015) 0.75
Distinct encounter complexes of PAI-1 with plasminogen activators and vitronectin revealed by changes in the conformation and dynamics of the reactive center loop. Protein Sci (2015) 0.75
Single fluorescence probes along the reactive center loop reveal site-specific changes during the latency transition of PAI-1. Protein Sci (2015) 0.75
Resolving distinct molecular origins for copper effects on PAI-1. J Biol Inorg Chem (2017) 0.75
Spectroscopic determination of tryptophan and tyrosine in proteins. Biochemistry (1967) 21.79
Plasminogen activators, tissue degradation, and cancer. Adv Cancer Res (1985) 8.64
Physiological consequences of loss of plasminogen activator gene function in mice. Nature (1994) 4.40
Structure of a serpin-protease complex shows inhibition by deformation. Nature (2000) 4.02
Plasminogen activation and cancer. Thromb Haemost (2005) 2.21
Is plasminogen activator inhibitor-1 the molecular switch that governs urokinase receptor-mediated cell adhesion and release? J Cell Biol (1996) 2.21
The plasminogen activator inhibitor PAI-1 controls in vivo tumor vascularization by interaction with proteases, not vitronectin. Implications for antiangiogenic strategies. J Cell Biol (2001) 1.94
Cancer invasion and tissue remodeling--cooperation of protease systems and cell types. APMIS (1999) 1.77
Purification and characterization of a plasminogen activator inhibitor 1 binding protein from human plasma. Identification as a multimeric form of S protein (vitronectin). J Biol Chem (1988) 1.77
How vitronectin binds PAI-1 to modulate fibrinolysis and cell migration. Nat Struct Biol (2003) 1.76
Molecular evolution of plasminogen activator inhibitor-1 functional stability. EMBO J (1995) 1.73
New roles for copper metabolism in cell proliferation, signaling, and disease. J Biol Chem (2008) 1.70
Plasminogen activator inhibitor-1 regulates tumor growth and angiogenesis. J Biol Chem (2001) 1.58
Characterization of human S protein, an inhibitor of the membrane attack complex of complement. Demonstration of a free reactive thiol group. Biochemistry (1985) 1.48
Pathogenic alpha 1-antitrypsin polymers are formed by reactive loop-beta-sheet A linkage. J Biol Chem (2000) 1.43
Inhibition of angiogenesis in vivo by plasminogen activator inhibitor-1. J Biol Chem (2000) 1.40
The active conformation of plasminogen activator inhibitor 1, a target for drugs to control fibrinolysis and cell adhesion. Structure (1999) 1.40
Serpin-protease complexes are trapped as stable acyl-enzyme intermediates. J Biol Chem (1995) 1.40
Active site distortion is sufficient for proteinase inhibition by serpins: structure of the covalent complex of alpha1-proteinase inhibitor with porcine pancreatic elastase. J Biol Chem (2005) 1.38
Structural and functional analysis of the plasminogen activator inhibitor-1 binding motif in the somatomedin B domain of vitronectin. J Biol Chem (1996) 1.31
Thrombolytic agents. Thromb Haemost (2005) 1.25
Copper(II)-induced self-oligomerization of alpha-synuclein. Biochem J (1999) 1.25
Plasminogen activator inhibitor-1 regulates cell adhesion by binding to the somatomedin B domain of vitronectin. J Cell Physiol (2001) 1.23
Tissue plasminogen activator in central nervous system physiology and pathology. Thromb Haemost (2005) 1.23
Resolution of Michaelis complex, acylation, and conformational change steps in the reactions of the serpin, plasminogen activator inhibitor-1, with tissue plasminogen activator and trypsin. Biochemistry (2001) 1.21
Mechanisms contributing to the conformational and functional flexibility of plasminogen activator inhibitor-1. Nat Struct Biol (1995) 1.20
Sedimentation analyses of the salt- and divalent metal ion-induced oligomerization of nucleolar protein B23. Biochemistry (1996) 1.19
Metal-mediated self-assembly of protein superstructures: influence of secondary interactions on protein oligomerization and aggregation. J Am Chem Soc (2008) 1.18
Structures of active and latent PAI-1: a possible stabilizing role for chloride ions. Biochemistry (2000) 1.13
Stability of plasminogen activator inhibitor 1 (PAI-1). Thromb Haemost (1989) 1.11
Engineering of plasminogen activator inhibitor-1 to reduce the rate of latency transition. Nat Struct Biol (1995) 1.09
Crystal structure of monomeric native antithrombin reveals a novel reactive center loop conformation. J Biol Chem (2006) 1.05
Characterization of the binding of different conformational forms of plasminogen activator inhibitor-1 to vitronectin. Implications for the regulation of pericellular proteolysis. J Biol Chem (1997) 1.01
Colocalization of thrombin, PAI-1, and vitronectin in the atherosclerotic vessel wall: A potential regulatory mechanism of thrombin activity by PAI-1/vitronectin complexes. Arterioscler Thromb Vasc Biol (2000) 0.99
Crystal structure of human maspin, a serpin with antitumor properties: reactive center loop of maspin is exposed but constrained. J Biol Chem (2004) 0.97
Alteration of vitronectin. Characterization of changes induced by treatment with urea. J Biol Chem (1993) 0.96
A deletion mutant of vitronectin lacking the somatomedin B domain exhibits residual plasminogen activator inhibitor-1-binding activity. J Biol Chem (2008) 0.93
Importance of the amino-acid composition of the shutter region of plasminogen activator inhibitor-1 for its transitions to latent and substrate forms. Eur J Biochem (2001) 0.92
Structure-function relationships in serpins: current concepts and controversies. Thromb Haemost (1998) 0.92
Mutation of the highly conserved tryptophan in the serpin breach region alters the inhibitory mechanism of plasminogen activator inhibitor-1. Biochemistry (2003) 0.91
Structural differences between active forms of plasminogen activator inhibitor type 1 revealed by conformationally sensitive ligands. J Biol Chem (2008) 0.91
The reactive-center loop of active PAI-1 is folded close to the protein core and can be partially inserted. J Mol Biol (2004) 0.91
Binding of plasminogen activator inhibitor type-1 to extracellular matrix of Hep G2 cells. Evidence that the binding protein is vitronectin. J Biol Chem (1991) 0.90
Interfering with the inhibitory mechanism of serpins: crystal structure of a complex formed between cleaved plasminogen activator inhibitor type 1 and a reactive-centre loop peptide. Structure (1998) 0.90
Disulfide bonding arrangements in active forms of the somatomedin B domain of human vitronectin. Biochemistry (2004) 0.90
A model for the three-dimensional structure of human plasma vitronectin from small-angle scattering measurements. Biochemistry (2005) 0.90
Uncontrolled zinc- and copper-induced oligomerisation of the human complement regulator factor H and its possible implications for function and disease. J Mol Biol (2008) 0.90
Characterization of a site on PAI-1 that binds to vitronectin outside of the somatomedin B domain. J Biol Chem (2008) 0.89
Physicochemical, immunochemical and functional comparison of human S-protein and vitronectin. Evidence for the identity of both plasma proteins. Biochem Biophys Res Commun (1986) 0.88
Characterization of the denaturation and renaturation of human plasma vitronectin. I. Biophysical characterization of protein unfolding and multimerization. J Biol Chem (1996) 0.88
High-resolution structure of the stable plasminogen activator inhibitor type-1 variant 14-1B in its proteinase-cleaved form: a new tool for detailed interaction studies and modeling. Protein Sci (2008) 0.87
The natural selection of the chemical elements. Cell Mol Life Sci (1997) 0.87
Mutational analysis of plasminogen activator inhibitor-1. Eur J Biochem (2003) 0.87
A structural basis for loop C-sheet polymerization in serpins. J Mol Biol (2008) 0.87
Biochemical importance of glycosylation of plasminogen activator inhibitor-1. Thromb Haemost (2003) 0.86
Specific binding of plasminogen to vitronectin. Evidence for a modulatory role of vitronectin on fibrin(ogen)-induced plasmin formation by tissue plasminogen activator. Biochem Biophys Res Commun (1990) 0.86
The serpins: nature's molecular mousetraps. Sci Prog (2001) 0.86
A peptide accelerating the conversion of plasminogen activator inhibitor-1 to an inactive latent state. Mol Pharmacol (2008) 0.84
Type 1 plasminogen activator inhibitor binds to fibrin via vitronectin. J Biol Chem (2000) 0.84
Crystal structure of S-ovalbumin as a non-loop-inserted thermostabilized serpin form. J Biol Chem (2003) 0.83
Metals affect the structure and activity of human plasminogen activator inhibitor-1. II. Binding affinity and conformational changes. Protein Sci (2011) 0.83
The significance of colocalization of plasminogen activator inhibitor-1 and vitronectin in hepatic fibrosis. Scand J Gastroenterol (1997) 0.82
The length of the reactive center loop modulates the latency transition of plasminogen activator inhibitor-1. Protein Sci (2004) 0.82
Effect of stabilizing versus destabilizing interactions on plasminogen activator inhibitor-1. Thromb Haemost (2000) 0.81
Interactions of plasminogen activator inhibitor-1 with vitronectin involve an extensive binding surface and induce mutual conformational rearrangements. Biochemistry (2009) 0.80
The localization of plasminogen activator inhibitor-1 in glomerular subepithelial deposits in membranous nephropathy. J Am Soc Nephrol (1996) 0.78
High-molecular-weight serum protein complexes differentially promote cell migration and the focal adhesion localization of the urokinase receptor in human glioma cells. Exp Cell Res (2000) 0.78
PAI-1 stability: the role of histidine residues. FEBS Lett (2000) 0.78
Dynamic structural and functional relationships in recombinant plasminogen activator inhibitor-1 (rPAI-1). Biochim Biophys Acta (1993) 0.77
Studying multiprotein complexes by multisignal sedimentation velocity analytical ultracentrifugation. Proc Natl Acad Sci U S A (2004) 2.74
Slow amyloid nucleation via α-helix-rich oligomeric intermediates in short polyglutamine-containing huntingtin fragments. J Mol Biol (2011) 1.17
Characterization of Novel Forms of Coagulation Factor XIa: independence of factor XIa subunits in factor IX activation. J Biol Chem (2008) 1.02
Activation of factor XI by products of prothrombin activation. Blood (2011) 0.99
Resolution of conformational activation in the kinetic mechanism of plasminogen activation by streptokinase. J Biol Chem (2004) 0.97
Exosite-mediated substrate recognition of factor IX by factor XIa. The factor XIa heavy chain is required for initial recognition of factor IX. J Biol Chem (2005) 0.95
A mechanism for assembly of complexes of vitronectin and plasminogen activator inhibitor-1 from sedimentation velocity analysis. J Biol Chem (2005) 0.94
Incorporation of vitronectin into fibrin clots. Evidence for a binding interaction between vitronectin and gamma A/gamma' fibrinogen. J Biol Chem (2001) 0.94
A deletion mutant of vitronectin lacking the somatomedin B domain exhibits residual plasminogen activator inhibitor-1-binding activity. J Biol Chem (2008) 0.93
A sequential mechanism for exosite-mediated factor IX activation by factor XIa. J Biol Chem (2012) 0.93
The dimeric structure of factor XI and zymogen activation. Blood (2013) 0.92
Solution structure of recombinant somatomedin B domain from vitronectin produced in Pichia pastoris. Protein Sci (2007) 0.91
A model for the three-dimensional structure of human plasma vitronectin from small-angle scattering measurements. Biochemistry (2005) 0.90
Binding of the COOH-terminal lysine residue of streptokinase to plasmin(ogen) kringles enhances formation of the streptokinase.plasmin(ogen) catalytic complexes. J Biol Chem (2006) 0.90
Characterization of a site on PAI-1 that binds to vitronectin outside of the somatomedin B domain. J Biol Chem (2008) 0.89
Vitronectin inhibits neutrophil apoptosis through activation of integrin-associated signaling pathways. Am J Respir Cell Mol Biol (2012) 0.88
The solution structure of the N-terminal domain of human vitronectin: proximal sites that regulate fibrinolysis and cell migration. J Biol Chem (2004) 0.88
Inhibition of neutrophil apoptosis by PAI-1. Am J Physiol Lung Cell Mol Physiol (2011) 0.87
Plasminogen activator inhibitor type 1 promotes the self-association of vitronectin into complexes exhibiting altered incorporation into the extracellular matrix. J Biol Chem (2002) 0.86
Role of the streptokinase alpha-domain in the interactions of streptokinase with plasminogen and plasmin. J Biol Chem (2004) 0.85
Sml1p is a dimer in solution: characterization of denaturation and renaturation of recombinant Sml1p. Biochemistry (2004) 0.85
Rational design of viscosity reducing mutants of a monoclonal antibody: hydrophobic versus electrostatic inter-molecular interactions. MAbs (2015) 0.85
Crystal structure of plasminogen activator inhibitor-1 in an active conformation with normal thermodynamic stability. J Biol Chem (2011) 0.84
Activation of the zymogen to urokinase-type plasminogen activator is associated with increased interdomain flexibility. J Mol Biol (2011) 0.83
Mutants of plasminogen activator inhibitor-1 designed to inhibit neutrophil elastase and cathepsin G are more effective in vivo than their endogenous inhibitors. J Biol Chem (2004) 0.83
Tissue-type plasminogen activator-plasmin-BDNF modulate glutamate-induced phase-shifts of the mouse suprachiasmatic circadian clock in vitro. Eur J Neurosci (2009) 0.83
Metals affect the structure and activity of human plasminogen activator inhibitor-1. II. Binding affinity and conformational changes. Protein Sci (2011) 0.83
Vitronectin inhibits efferocytosis through interactions with apoptotic cells as well as with macrophages. J Immunol (2013) 0.81
A concerted structural transition in the plasminogen activator inhibitor-1 mechanism of inhibition. Biochemistry (2002) 0.81
Interactions of plasminogen activator inhibitor-1 with vitronectin involve an extensive binding surface and induce mutual conformational rearrangements. Biochemistry (2009) 0.80
R67, the other dihydrofolate reductase: rational design of an alternate active site configuration. Biochemistry (2007) 0.79
Assignment of the four disulfides in the N-terminal somatomedin B domain of native vitronectin isolated from human plasma. J Biol Chem (2004) 0.79
Sucrose octasulfate selectively accelerates thrombin inactivation by heparin cofactor II. J Biol Chem (2010) 0.79
Thermodynamic characterization of a thermostable antibiotic resistance enzyme, the aminoglycoside nucleotidyltransferase (4'). Biochemistry (2012) 0.78
Glycosaminoglycan-binding properties and kinetic characterization of human heparin cofactor II expressed in Escherichia coli. Anal Biochem (2010) 0.78
Radical redesign of a tandem array of four R67 dihydrofolate reductase genes yields a functional, folded protein possessing 45 substitutions. Biochemistry (2010) 0.78
Correction to Thermodynamic Characterization of a Thermostable Antibiotic Resistance Enzyme, the Aminoglycoside Nucleotidyltransferase (4'). Biochemistry (2015) 0.75
Alprazolam induced conformational change in hemoglobin. Int J Biol Macromol (2006) 0.75